Search PubMed⌕ Search

Biomedical subjects

J W Hay

Publications and source records attributed to J W Hay.

At least 37 records · Page 2Linked to original sources
PubMed1992

Inflammatory bowel disease: costs-of-illness.

We have evaluated the economic costs to society for the two major types of inflammatory bowel disease, Crohn's disease and ulcerative colitis, using a medical decision algorithm costing methodology augmented by examination of 1988-89 claims data from a major U.S. commercial insurer. The average annual medical cost per patient with Crohn's disease was estimated at $6,561 (1990 U.S. dollars). The total annual medical costs for U.S. Crohn's disease patients in 1990 was estimated at $1.0-1.2 billion. The average annual medical cost per patient with ulcerative colitis was estimated at $1,488. The total annual medical costs for U.S. patients with ulcerative colitis in 1990 was estimated at $0.4-0.6 billion. Adjusting for productivity losses, we estimated the annual economic cost for both diseases at $1.8 billion to $2.6 billion. Analysis of insurance claims data for inflammatory bowel disease patients showed that the distribution of annual medical expenses charged and paid is highly uneven by patient. The top 2% of Crohn's disease patients accounted for 28.9% of total charges and 34.3% of the total amount paid. The top 2% of ulcerative colitis patients accounted for 36.2% of total charges and 39.0% of the total amount paid. We used a multivariate regression model to examine potential cost-effectiveness tradeoffs between different types of medical services in treatment of inflammatory bowel disease.

Adult↗
PubMed1992

Inflammatory bowel disease: medical cost algorithms.

In this study we describe medical cost estimates for the two major types of inflammatory bowel disease, Crohn's disease and ulcerative colitis, using a literature-based medical decision algorithm costing methodology. Surgery and inpatient costs were estimated to account for roughly half of inflammatory bowel disease medical costs. Outpatient medical care represented only 3.0-7.1% of average cost of medical care for inflammatory bowel disease; initial diagnostic workups were only 1.5-7.8% of medical costs. Long-term complications were estimated to average $439 for ulcerative colitis, nearly twice the average for Crohn's disease. Medications averaged about 10% of total costs. The average annual medical cost per patient with Crohn's disease was estimated at $6,561 (1990 U.S. dollars). The total annual medical costs for U.S. Crohn's disease patients in 1990 was estimated at $1.0-1.2 billion. The average annual medical cost per patient with ulcerative colitis was estimated at $1,488. The total annual medical costs for U.S. patients with ulcerative colitis in 1990 was estimated at $0.4-0.6 billion.

Algorithms↗
PubMed1991

An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction.

The costs and benefits of cholesterol lowering in the primary prevention of coronary artery disease (CAD) were considered using lifetime lovastatin therapy as the intervention model for adults between 35 and 55 years of age. The analysis projected the benefits of CAD risk reduction using estimates from the Framingham Heart Study. The chosen analytic perspective was that of the patient. For average-risk men with total serum cholesterol levels between 5.69 and 9.83 mmol/liter (220 and 380 mg/dl), the cost per life-year saved ranged from $9,000 to $106,000, whereas for average-risk women, the cost ranged from $35,000 to $297,000 (1989 U.S. dollars). In high-risk men (with smoking habit and hypertension), the cost per life-year saved values ranged from 6,000 to $53,000, whereas in high-risk women the cost per life-year saved values ranged from $19,000 to $160,000. The results were more favorable than those found in previous studies of alternate medication therapies for hypercholesterolemia. Even using conservative parameter assumptions, at least 800,000 Americans aged 35 to 55 years are at sufficiently high risk for CAD, so that the net cost of lovastatin therapy can be favorably compared with other widely used medical interventions.

Adult↗
PubMed1991

Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease.

BACKGROUND: Alpha 1-antitrypsin (AAT) replacement therapy is an expensive intervention ($20,000-$30,000 per patient annually) which may slow or arrest the progression of chronic obstructive pulmonary disease (COPD) in AAT-deficient patients. While FDA-approved, therapy efficacy is unknown. The costs and benefits of AAT replacement therapy were evaluated for patients with congenital COPD. METHODS: Epidemiological and disease cost data were taken from published sources. A discrete-time model of disease stage probability transition was developed to calculate the present-value expected cost of disease treatment, under a range of possible therapy efficacy and other parameter values. RESULTS: At an efficacy of 70 percent, the cost per life year saved with AAT replacement therapy would be between $28,000 and $72,000 (1990 US dollars), depending on patient age, sex, and smoking status. At 30 percent efficacy, the cost per life year saved range would be between $50,000 and $128,000. A controlled efficacy study would cost $53 million or less, if the true efficacy were 50 percent or better. CONCLUSIONS: With efficacy of 30 percent or higher, therapy cost-effectiveness would be comparable to other widely used medical interventions. The economic assessment methodology was used to evaluate both the therapeutic innovation and the value of additional clinical research.

Adult↗
PubMed1990

Medical costs of coronary artery disease in the United States.

A model has been developed to determine the cost of coronary artery disease (CAD) based on the 5 primary events identified in the Framingham Study: acute myocardial infarction, angina pectoris, unstable angina pectoris, sudden death and nonsudden death. The costs for diagnostic and therapeutic service for patients with CAD were linked to medical decision algorithms outlining the diagnosis and management of patients with CAD. Because CAD is a changing illness not represented by a single event, the algorithm tracked patients for 5 years after the time of diagnosis, or until death, to develop average cost estimates. The estimated 5-year costs (in 1986 United States dollars) of the 5 CAD events were: acute myocardial infarction $51,211, angina pectoris $24,980, unstable angina pectoris $40,581, sudden death $9,078 and nonsudden death $19,697. The costs of major CAD surgical procedures were also calculated because of their impact on health care costs for patients with CAD. These include: coronary artery bypass surgery per case over 5 years $32,465, and angioplasty per case over 5 years $26,916. The high cost of CAD reflects the improved technology and more effective and expensive therapies now available.

Algorithms↗
PubMed1990

Cost-benefit analysis of Haemophilus influenzae type b prevention: conjugate vaccination at eighteen months of age.

A cost-benefit analysis of Haemophilus influenzae type b disease preventive strategies was updated to consider evaluation of the H. influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D) and H. influenzae type b oligosaccharide-mutant diphtheria toxin conjugate vaccine (HbOC) for children at 18 months of age. The analysis was done from the perspective of society as a whole. The economic costs of H. influenzae type b disease in the 1988 United States birth cohort would be $2.546 billion (1988 U.S. dollars) in the absence of preventive efforts. If 60% of all children could be vaccinated with PRP-D or HbOC at 18 months of age, this strategy would save $207.1 million ($88.22 savings/vaccinee; $43,605 cost/case prevented; 3.57/1 benefit-to-cost ratio) under base case model assumptions. Universal PRP-D or HbOC vaccination at 18 months of age would prevent 1845 cases of invasive H. influenzae type b disease. The break-even efficacy for universal PRP-D or HbOC vaccination at 18 months of age was 22.7%. We conclude that, under the model base case assumptions, universal PRP-D or HbOC vaccination at 18 months of age is sufficiently efficacious so that the costs of vaccination would be more than offset by decreased medical care costs for treating H. influenzae type b disease.

Bacterial Vaccines↗
PubMed1989

Econometric issues in modeling the costs of AIDS.

The goals of AIDS or HIV econometric modeling efforts are: (i) to evaluate or project the costs-of-illness to the individual and to society; and (ii) to examine the efficiency and cost-effectiveness of medical and social services provided to patients. Most of the standard theoretical and statistical approaches are not applicable because of the scarcity, incompleteness and non-representative nature of available data. This paper discusses specific methodological approaches concerning AIDS and HIV epidemiology, medical cost estimation techniques, evaluation of the cost-effectiveness of social support programs and valuation of human life. The epidemiologic projection approach--a simplified 'back calculation' method--suggests that the number of Americans infected with the AIDS virus in 1987-88 was likely to be between 500,000 and 800,000. This estimate is between 2 and 3 times lower than the U.S. Centers for Disease Control estimates. Methods for estimating both the direct and indirect costs of illness are described.

Acquired Immunodeficiency Syndrome↗
PubMed1988

Projecting the medical costs of AIDS and ARC in the United States.

We projected the direct medical costs of acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) for the United States during the period 1987-1991, by applying current epidemiologic projections to state-of-the-art medical decision algorithms for diagnosis and treatment of AIDS-related illnesses. We included the cost of azidothymidine (AZT) therapy, as well as other therapeutic innovations likely to be approved by the FDA, and estimated average ARC patient treatment costs. By combining prospective study data on rates of progression to AIDS with current AIDS incidence data, we arrived at human immunodeficiency virus (HIV) seroprevalence and AIDS incidence projection that were considerably lower than those of the Public Health Service. We estimated the average total medical costs per patient for AIDS in the 1990s at $27,950-$40,455 and for ARC at $3,621-$4,913 per year (1987 U.S. dollars). We projected the medical costs of AIDS and ARC at $2-4 billion annually by 1991, substantially lower than previous estimates. We projected that Pneumocystis carinii pneumonia and other pulmonary complications would account for the largest share (over 40%) of AIDS medical costs, and that AZT therapy and medication would account for more than 25% of total ARC/AIDS treatment costs by 1991. In our estimates, the total medical costs of treating ARC patients could approach one-half of the costs of treating AIDS patients by 1991, primarily due to costs associated with AZT.

AIDS-Related Complex↗
PubMed1988

Cost-effectiveness of three transdermal nitroglycerin controlled-release systems.

We performed cost-effectiveness analyses of three transdermal nitroglycerin systems--TDN, ND II, and NTS--using data from two studies that compared these systems in terms of adhesive properties, patients' preferences, and skin tolerability. The purpose of our analysis was to determine which system achieved treatment objectives at the lowest cost. On the basis of data from the first of the two studies, the better adhesion and tolerability profile of TDN in comparison with ND II resulted in a savings of 2.8% and 4.4% at the wholesale and retail levels, respectively, for TDN over a four-week period. In a multivariate regression analysis of these data, the savings with TDN increased to 11% at wholesale prices and 12.7% at retail prices. For Study 2, retail and wholesale costs were found to be lower with the NTS patch than with the TDN patch in both the direct comparison and the multivariate analysis. However, extremely high rates of adverse reactions at the site of patch application-42%-and withdrawals due to adverse effects-64%-were noted in the NTS group; the corresponding rates in the TDN group were 2% and 0%. As a result, the cost advantage noted for the NTS patch was eliminated when the superior adhesion and tolerability characteristics of the TDN patch were considered in the analysis of the overall costs to the patient.

Adhesives↗
PubMed1987

The economic costs of Alzheimer's disease.

This paper estimates the economic costs of Alzheimer's Disease to individuals and to society, based on review of published Alzheimer's Disease-related research. The analysis is derived from epidemiological projections and cost information for the United States population in 1983. Estimated costs include both direct medical care and social support costs, as well as indirect costs, such as support services provided by family or volunteers, and the value of lost economic productivity in Alzheimer's Disease patients. Mid-range estimates of net annual expected costs for an Alzheimer's Disease patient, excluding the value of lost productivity, are $18,517 in the first year and $17,643 in subsequent years, with direct medical and social services comprising about half of these costs. Under base case assumptions, the total cost of disease per patient in 1983, was $48,544 to $493,277, depending upon patient's age at disease onset. The estimated present value of total net costs to society for all persons first diagnosed with Alzheimer's Disease in 1983 was $27.9-31.2 billion. Development of a public or private insurance market for the economic burdens of Alzheimer's Disease would fill some of the gaps in the current US system of financing long-term chronic disease care.

Aged↗
PubMed1987

Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection.

A cost-benefit analysis for Haemophilus influenzae type b disease prevention was developed to examine two officially recommended preventive strategies: H influenzae type b capsular polysaccharide immunization and rifampin prophylaxis of exposed contacts. The social costs of H influenzae type b disease in the 1984 US birth cohort will be $1.937 billion when base case assumptions are made. If it is assumed that 60% of all children could be vaccinated at 24 months of age, universal vaccination has the highest economic benefits of any single preventive strategy considered (net savings $64.8 million). Rifampin prophylaxis of appropriate household contacts has the highest benefit to cost ratio (59:1), but because rifampin prevents only secondary disease, only half as many cases can be prevented with rifampin prophylaxis of appropriate household contacts (501 cases prevented, $1,994 per case prevented) as with universal vaccination at 24 months (985 cases prevented, $63,484 per case prevented). Single-dose vaccination of day-care attendees at 18 months of age is the most expensive preventive strategy considered ($148,445 per case prevented, 306 cases prevented). Rifampin prophylaxis of appropriate day-care contacts prevents the fewest H influenzae type b cases ($46,041 per case prevented, 72 cases prevented.

Adolescent↗
PubMed1985

Cost-effectiveness of two transdermal nitroglycerin controlled-release systems.

An analysis of the cost-effectiveness of two transdermal nitroglycerin systems utilizing adhesive patches, TDN and ND, was performed by a health-care research and management consulting firm. Better adhesion of TDN produced an estimated 14.5% savings over ND ($22.93 vs $26.82) in wholesale prescription costs for four weeks. Multivariate regression analyses, which controlled for patients' age, sex, body mass index, and study location, did not affect the observed difference in adhesive properties, suggesting that TDN's adhesive superiority is intrinsic to patch function and that it does not depend on other variables.

Adhesiveness↗
PubMed1984

Home health care cost-function analysis.

An exploratory home health care (HHC) cost-function model is estimated using State rate-setting data for the 74 traditional (nonprofit) Connecticut agencies. The analysis demonstrates U-shaped average costs curves for agencies' provision of skilled nursing visits, with substantial diseconomies of scale in the observable range. It is determined from the estimated cost function that the sample representative agency is providing fewer visits than optimal, and its marginal cost is significantly below average cost. The finding that an agency's costs are predominantly related to output levels, with little systematic variation due to other agency or patient characteristics, suggests that the economic inefficiency in a cost-based HHC reimbursement policy may be substantial.

Analysis of Variance↗
PubMed1983

The impact of public health care financing policies on private-sector hospital costs.

Two of the best-known economic models of hospital behavior are utilized to examine theoretically the issue of cross-subsidization of hospital costs between public and private-pay patients. It is shown that the existence of public/private hospital-charge differentials does not, in itself, demonstrate that public programs are subsidized by the private sector. This differential is to be expected, whether hospitals are considered to be monopolistic profit maximizers or controlled by physicians. While cost-based hospital reimbursement may be dynamically inefficient, it is shown to have certain static efficiency properties when hospitals provide services to both public and private patients.

Costs and Cost Analysis↗